Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 755 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Glaucoma, Ocular Hypertension
Interventions: T4090 0.2%, T4090 0.3%, Rhopressa®; Drug
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 24
States / cities: Glendale, Arizona • Glendale, California • Inglewood, California + 19 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Travoprost, Latanoprost; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: LL-BMT1; Drug
Lead sponsor: MediPrint Ophthalmics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma
Interventions: OCT scanning and HFA perimetry; Device
Lead sponsor: Carl Zeiss Meditec, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Dublin, California

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Travoprost/brinzolamide; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Artesia, California

Conditions: Glaucoma
Interventions: latanoprost 0.005%, Placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Palm Beach Gardens, Florida

Conditions: Normal Tension Glaucoma
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years to 101 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: New York, New York

Conditions: Eye Diseases, Visual Impairment, Glaucoma
Interventions: Standard optometric examination, Technology enhanced eye disease detection protocol; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Glaucoma
Interventions: TEMPO iMOvifa; Diagnostic Test
Lead sponsor: Cape Fear Eye Institute; Other
Eligibility: 40 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Glaucoma, Ocular Hypertension
Interventions: Travoprost; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Call For Details, Nebraska

Conditions: Age Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions: Text Message Reminder, Health Worker Visit; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: Survey; Other
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: Not listed
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Interventions: Latanoprost ophthalmic solution, AKB-9778 4%, Placebo; Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 21
States / cities: Inglewood, California • Mission Hills, California • Newport Beach, California + 18 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: BOL-303259-X, Timolol; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Open Angle Glaucoma (OAG)
Interventions: DSLT enables newly diagnosed patients to remain well controlled and off medications; Device
Lead sponsor: Barnet Dulaney Perkins Eye Centers; Network
Eligibility: 30 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Active Comparator: Timolol 0.5%, Sham: Applicator Without Needle, Timolol Vehicle (placebo); Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 56
States / cities: Phoenix, Arizona • Glendale, California • Irvine, California + 51 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: RKI983A, Latanoprost; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 29
States / cities: Artesia, California • Inglewood, California • La Jolla, California + 25 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: ATS907; Drug
Lead sponsor: Altheos, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Artesia, California

Conditions: Ocular Hypertension
Interventions: C-KAD Ophthalmic Solution; Drug
Lead sponsor: Chakshu Research, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C, Latanoprost 0.005% eye drops; Drug
Lead sponsor: ViSci Ltd.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bellevue, Washington

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: JV-GL1, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: JeniVision, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Open Angle Glaucoma
Interventions: Hydrus Microstent; Device
Lead sponsor: InSight Vision Center Medical Group, Inc; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Fresno, California

Search by objective public record fields.

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Study of LL-BMT1 in Patients With Elevated Intraocular Pressure

Glaucoma HFA / OCT Specificity Study

Does Lowering Eye Pressure Affect the Results Obtained From Objective Visual Field Testing?

IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension

Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo

A New View of Normal Tension Glaucoma: Autoregulation and Systemic Blood Pressure

Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2

Glaucoma Screening

Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

Strategies for Improving Linkage-to-Care After Eye Disease Screening

Survey of Patients Taking IOP-Lowering Eye Drops

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects

An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Hydrus Microstent as a Quality of Life Consideration